Longitudinal brain changes in MDD during emotional encoding: effects of presence and persistence of symptomatology
Ai, H.; Opmeer, E.M.; Marsman, J.B.C.; Veltman, D.J.; Wee, N.J.A. van der; Aleman, A.; Tol, M.J. van

Citation

Version: Publisher's Version
License: Creative Commons CC BY-NC-ND 4.0 license
Downloaded from: https://hdl.handle.net/1887/3184515

Note: To cite this publication please use the final published version (if applicable).
Longitudinal brain changes in MDD during emotional encoding: effects of presence and persistence of symptomatology

Hui Ai1,2, Esther M. Opmeer2, Jan-Bernard C. Marsman2, Dick J. Veltman3,4, Nic J. A. van der Wee5,6, André Aleman1,2 and Marie-José van Tol2

1Shenzhen Key Laboratory of Affective and Social Neuroscience, Center for Brain Disorders and Cognitive Sciences, Shenzhen University, Shenzhen, China; 2Cognitive Neuroscience Center, Department of Biomedical Sciences of Cells and Systems, University Medical Center Groningen, Groningen, The Netherlands; 3Department of Psychiatry, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; 4Department of Anatomy and Neurosciences, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; 5Department of Psychiatry, Leiden University Medical Center, Leiden, The Netherlands and 6Leiden University, Leiden Institute for Brain and Cognition, Leiden, The Netherlands

Abstract

Background. The importance of the hippocampus and amygdala for disrupted emotional memory formation in depression is well-recognized, but it remains unclear whether functional abnormalities are state-dependent and whether they are affected by the persistence of depressive symptoms.

Methods. Thirty-nine patients with major depressive disorder and 28 healthy controls were included from the longitudinal functional magnetic resonance imaging (fMRI) sub-study of the Netherlands Study of Depression and Anxiety. Participants performed an emotional word-encoding and -recognition task during fMRI at baseline and 2-year follow-up measurement. At baseline, all patients were in a depressed state. We investigated state-dependency by relating changes in brain activation over time to changes in symptom severity. Furthermore, the effect of time spent with depressive symptoms in the 2-year interval was investigated.

Results. Symptom change was linearly associated with higher activation over time of the left anterior hippocampus extending to the amygdala during positive and negative word-encoding. Especially during positive word encoding, this effect was driven by symptomatic improvement. There was no effect of time spent with depression in the 2-year interval on change in brain activation. Results were independent of medication- and psychotherapy-use.

Conclusion. Using a longitudinal within-subjects design, we showed that hippocampal–amygdalar activation during emotional memory formation is related to depressive symptom severity but not persistence (i.e. time spent with depression or ‘load’), suggesting functional activation patterns in depression are not subject to functional ‘scarring’ although this hypothesis awaits future replication.

Introduction

Major depressive disorder (MDD) is a prevalent psychiatric disorder associated with high morbidity and mortality, frequently characterized by a chronic or recurrent course (Kessler et al., 2005). Biased emotional memory has been proposed as a key factor for the development and maintenance of MDD (Leppänen, 2006; Disner et al., 2011; Ai et al., 2015; Everaert et al., 2015) and may even underlie the vulnerability for depressive psychopathology (Chan et al., 2007). Cross-sectional studies suggested that emotional memory biases are state-independent phenomena: better memory for negative information and worse memory for positive information have been reported during both the acute depressive state and during remission [reviewed elsewhere (Bradley and Mathews, 1988; Elliott et al., 2010)], mirroring functional brain abnormalities observed in areas critical for memory formation of emotional material, i.e. the amygdala and hippocampus (Ramel et al., 2007; Arnold et al., 2011; van Tol et al., 2012). Previously, we however observed hyperactivation of the anterior hippocampus/amygdala during encoding of negative information in acutely depressed patients but not in remitted patients in a cross-sectional comparison (van Tol et al., 2012), suggesting state-dependency instead. However, cross-sectional studies do not allow strong inferences on state-dependency. Importantly, identifying state-dependent neurocognitive markers of MDD may constitute a first step in understanding mechanisms of recovery vs. maintenance of depression (Mayberg, 1997; Maalouf et al., 2012; Dohm et al., 2017).

While longitudinal neuropsychological studies have found that memory biases resolve upon recovery after treatment (Calev et al., 1986; Peselow et al., 1991) (though not consistently in Sternberg and Jarvik, 1976), functional neuroimaging studies reported mostly changes in...
activation of the amygdala and hippocampus following symptom- 
atic improvement during affective processing (i.e. not in the 
context of memory processing) or rest. Findings have been 
inconclusive with reports of decreased (Sheline et al., 2001; Fu 
et al., 2004; Redlich et al., 2017), increased (Goldapple et al., 
2004; Neumeister et al., 2006; Victor et al., 2010; Ritchey et al., 
2011), or unchanged (Fu et al., 2015; Opmeer et al., 2015) activa-
tion following successful short-term pharmacological treatment 
(Sheline et al., 2001; Fu et al., 2004; Victor et al., 2010; Fu 
et al., 2015), electroconvulsive therapy (Redlich et al., 2017), cog-
nitive behavioral treatment (Fu et al., 2008; Goldapple et al., 2004; 
Ritchey et al., 2011), or naturalistic remission (Opmeer et al., 
2015). Heterogeneity in findings may be partly explained by 
methodological factors such as small sample size, type of stimuli, 
effects of the (pharmacological) treatment itself on blood flow, or 
clinical variation in terms of comorbidity or interval between pre-
and post-measurement. Nevertheless, the effects of symptomatic 
reconstructed retrospectively based on self-reports at the 2-year 
follow-up interview. We hypothesized that changes in activation of the amygdala and hip-
causality at S2 (i.e. MADRS-score >10; Zimmerman et al., 2004). One participant had a 
huge increase in MADRS score at S2 and was classified as an out-
liner (change score >3SD from group mean) and subsequently 
excluded from the analyses. The final patient sample included 
39 individuals. In total, 11 HC were excluded from further 
analysis based on the presence of possible depressive symptom-
atology at S2 (i.e. MADRS-score >10; n = 1), too high level of 
education to be matched to the patient group (n = 1), or unreli-
able task performance (n = 9; online Supplementary Fig. S1). 
This resulted in the inclusion of 28 HC without any current or 
life-time DSM-IV diagnosis and no indication of depressive 
symptomatology at both S1 and S2 (see online Supplementary 
Fig. S1 for a flow diagram reflecting data selection).

Methods and materials

Participants

Participants were recruited from the ongoing neuroimaging sub-
study of the NESDA (Penninx et al., 2008) and underwent fMRI

scanning at the University Medical Center Groningen (UMCG), 
Academic Medical Center (AMC) of the University of 
Amsterdam, and the Leiden University Medical Center 
(LUMC). NESDA has been designed as a longitudinal observa-
tional cohort study with measurements at baseline, 1-, 2-, 4-, 
6-, and 9-year follow-up, with MRI measurements performed in 
asubsample at baseline, 2- and 9-year follow-up (9-year 
follow-up measurement was completed during the preparation of 
this manuscript). At baseline, patients with MDD (n = 70), 
MDD and one or more anxiety disorders [i.e. social anxiety dis-
order (SAD), panic disorder (PD), and/or generalized anxiety dis-
order (GAD); N = 92], patients with only anxiety disorders (i.e. 
SAD, PD, and/or GAD; n = 71), and healthy control participants 
(HC; n = 68) were included. The ethical review board of each par-
ticipating center approved the study and all participants gave writ-
en informed consent.

Exclusion criteria for all participants in the NESDA neuroima-
ging study at baseline (n = 301) were: age under 18 or over 57 
years; current alcohol or substance abuse; presence or history of 
a neurological or somatic disorder with possible effects on the 
central nervous system; general 3T MRI contraindications; hyper-
tension. Use of selective serotonin reuptake inhibitors (SSRIs) or 
infrquent use of benzodiazepines [oxazepam (max 20 mg) or 
diazepam, maximum of three times a week and not within 48 h 
before scanning] was allowed. Patients using any other psycho-
pharmacological agent were excluded. Exclusion criteria for the 
second measurement at 2-year follow-up (S2; N = 199) were 
identical, with the exception of the age criterion. Also, from a cohort 
perspective, we were less strict in excluding patients based on the 
type of medication used at S2 (see Table 1 and online 
Supplementary Table S1 for details). In line with the observational 
nature of the NESDA study, no specific treatment was delivered in 
between measurements, but was monitored retrospectively. 
Participants were free to consult their general practitioner, psychi-
atrist or psychologist for the help they wished to receive. 
Results of the baseline measurement (S1) and their associations 
with subsequent course related to emotional memory processing 
have been published elsewhere (van Tol et al., 2012; Ai et al., 
2015).

Complete behavioral data and good quality fMRI data at both 
S1 and S2 were available for 64 MDD patients and 39 HC. At S1, 
all patients fulfilled the criteria for a diagnosis of MDD with a 
half-year recency based on the Composite International 
Diagnostic Interview (CIDI life time – version 2). An additional 
diagnosis of SAD, PD, and/or GAD at either S1 or S2 was allowed 
(see Table 1 for details). Following Opmeer et al. (2015), we 
included only patients who were in a depressive state at S1 defined 
as a Montgomery–Åsberg Depression Rating Scale (MADRS) 
score >10 (Zimmerman et al., 2004). One participant had a 
huge increase in MADRS score at S2 and was classified as an out-
liner (change score >3SD from group mean) and subsequently 
excluded from the analyses. The final patient sample included 
39 individuals. In total, 11 HC were excluded from further 
analysis based on the presence of possible depressive symptom-
atology at S2 (i.e. MADRS-score >10; n = 1), too high level of 
education to be matched to the patient group (n = 1), or unreli-
able task performance (n = 9; online Supplementary Fig. S1). 
This resulted in the inclusion of 28 HC without any current or 
life-time DSM-IV diagnosis and no indication of depressive 
symptomatology at both S1 and S2 (see online Supplementary 
Fig. S1 for a flow diagram reflecting data selection).
<table>
<thead>
<tr>
<th></th>
<th>HC</th>
<th>High-improved MDD</th>
<th>Low-improved MDD</th>
<th>F</th>
<th>t</th>
<th>$\chi^2$</th>
<th>Likelihood ratio</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>$N$</td>
<td>28</td>
<td>19</td>
<td>20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diagnosis over time (remitted/non-remitted)</td>
<td>N</td>
<td>–</td>
<td>17/2</td>
<td>9/10</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>State change over time (improved/stable/worsen)</td>
<td>N</td>
<td>–</td>
<td>19/0/0</td>
<td>14/2/4</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Site S1 (AMC/LUMC/UMCG)</td>
<td>N</td>
<td>15/9/4</td>
<td>8/8/3</td>
<td>8/8/4</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>1.51</td>
</tr>
<tr>
<td>Site S2 (AMC/LUMC/UMCG)</td>
<td>N</td>
<td>13/11/4</td>
<td>7/9/3</td>
<td>8/8/4</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>0.70</td>
</tr>
<tr>
<td>Sex (male/female)</td>
<td>N</td>
<td>10/18</td>
<td>7/12</td>
<td>9/11</td>
<td>–</td>
<td>0.47</td>
<td>–</td>
<td>0.79</td>
</tr>
<tr>
<td>Age (M (S.D.))</td>
<td>M</td>
<td>39.82 (9.68)</td>
<td>37.32 (9.59)</td>
<td>39.55 (11.26)</td>
<td>0.38</td>
<td>–</td>
<td>–</td>
<td>0.68</td>
</tr>
<tr>
<td>Years of education (M (S.D.))</td>
<td>M</td>
<td>14.46 (2.77)</td>
<td>12.37 (2.17)</td>
<td>13.60 (3.78)</td>
<td>2.83</td>
<td>–</td>
<td>–</td>
<td>0.07</td>
</tr>
<tr>
<td>Months interval (M (S.D.))</td>
<td>M</td>
<td>21.85 (1.38)</td>
<td>22.63 (1.30)</td>
<td>22.20 (1.61)</td>
<td>1.66</td>
<td>–</td>
<td>–</td>
<td>0.20</td>
</tr>
<tr>
<td>MADRS_S1 (M (S.D.))</td>
<td>M</td>
<td>0.93 (1.44)</td>
<td>19.11 (5.17)</td>
<td>21.55 (7.33)</td>
<td>127.5</td>
<td>–</td>
<td>–</td>
<td>&lt;0.001**</td>
</tr>
<tr>
<td>MADRS_S2 (M (S.D.))</td>
<td>M</td>
<td>0.50 (1.00)</td>
<td>4.16 (2.83)</td>
<td>17.90 (6.37)</td>
<td>126.0</td>
<td>–</td>
<td>–</td>
<td>&lt;0.001**</td>
</tr>
<tr>
<td>Relative MADRS_S2 &gt; S1 (M (S.D.))</td>
<td>M</td>
<td>–0.81 (0.36)</td>
<td>–0.78 (0.15)</td>
<td>–0.14 (0.29)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>&lt;0.001**</td>
</tr>
<tr>
<td>BAI_S1 (M (S.D.))</td>
<td>M</td>
<td>2.07 (2.70)</td>
<td>12.32 (7.33)</td>
<td>15.15 (9.76)</td>
<td>24.83</td>
<td>–</td>
<td>–</td>
<td>&lt;0.001**</td>
</tr>
<tr>
<td>BAI_S2 (M (S.D.))</td>
<td>M</td>
<td>2.14 (2.03)</td>
<td>7.58 (5.61)</td>
<td>14.10 (8.50)</td>
<td>26.08</td>
<td>–</td>
<td>–</td>
<td>&lt;0.001**</td>
</tr>
<tr>
<td>Relative BAI_S2 &gt; S1 (M (S.D.))</td>
<td>M</td>
<td>0.02 (0.99)</td>
<td>–0.45 (0.38)</td>
<td>0.45 (1.92)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>0.07</td>
</tr>
<tr>
<td>Depressive duration between S1 and S2 (%) (M (S.D.))</td>
<td>M</td>
<td>–</td>
<td>0.42 (0.40)</td>
<td>0.58 (0.40)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>0.23</td>
</tr>
<tr>
<td>Months with depressive symptom before S1 (M (S.D.))</td>
<td>M</td>
<td>–</td>
<td>16.42 (14.69)</td>
<td>22.85 (16.28)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>0.20</td>
</tr>
<tr>
<td>Comorbidity_S1 (MDD/MDD*)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comorbid SAD</td>
<td>N</td>
<td>–</td>
<td>6/13</td>
<td>9/11</td>
<td>–</td>
<td>–</td>
<td>0.74</td>
<td>0.51</td>
</tr>
<tr>
<td>Comorbid PD</td>
<td>N</td>
<td>–</td>
<td>6/13</td>
<td>6/14</td>
<td>–</td>
<td>–</td>
<td>0.01</td>
<td>0.92</td>
</tr>
<tr>
<td>Comorbid GAD</td>
<td>N</td>
<td>–</td>
<td>7/12</td>
<td>10/10</td>
<td>–</td>
<td>–</td>
<td>67</td>
<td>0.52</td>
</tr>
<tr>
<td>Comorbidity at follow-up</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comorbid SAD (yes/no)</td>
<td>N</td>
<td>–</td>
<td>2/17</td>
<td>6/14</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>2.36</td>
</tr>
<tr>
<td>Comorbid PD (yes/no)</td>
<td>N</td>
<td>–</td>
<td>2/17</td>
<td>6/14</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>2.36</td>
</tr>
<tr>
<td>Comorbid GAD (yes/no)</td>
<td>N</td>
<td>–</td>
<td>0/19</td>
<td>8/12</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>12.66</td>
</tr>
<tr>
<td></td>
<td>M (s.d.)</td>
<td>–</td>
<td>26.89 (11.27)</td>
<td>21.74 (9.76)</td>
<td>–</td>
<td>1.51</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>----------</td>
<td>-------</td>
<td>---------------</td>
<td>--------------</td>
<td>-------</td>
<td>------</td>
<td>-------</td>
<td>-------</td>
</tr>
<tr>
<td>Age of depressive onset</td>
<td></td>
<td>–</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td># of episodes prior to S1</td>
<td>M (s.d.)</td>
<td>–</td>
<td>1.36 (0.67)</td>
<td>1.64 (0.67)</td>
<td>–</td>
<td>−0.95</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Psychotherapy-use_S1</td>
<td>M (s.d.)</td>
<td>–</td>
<td>4/15</td>
<td>6/14</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Psychotherapy-use_S2</td>
<td>M (s.d.)</td>
<td>–</td>
<td>9/10</td>
<td>6/14</td>
<td>–</td>
<td>–</td>
<td>1.24</td>
<td>–</td>
</tr>
<tr>
<td>Psychotherapy-use between S1 and S2 (both used/stopped after S1/started after S1/both not used)</td>
<td>M (s.d.)</td>
<td>–</td>
<td>10/5/0/4</td>
<td>12/2/2/4</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>SSRI-use_S1 (yes/no)</td>
<td>N</td>
<td>–</td>
<td>7/12</td>
<td>7/13</td>
<td>–</td>
<td>–</td>
<td>0.01</td>
<td>–</td>
</tr>
<tr>
<td>SSRI-use_S2 (yes/no)</td>
<td>N</td>
<td>–</td>
<td>7/12</td>
<td>3/17</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>SSRI-use between S1 and S2 (both used/stopped after S1/started after S1/both not used)</td>
<td>N</td>
<td>–</td>
<td>5/2/2/10</td>
<td>2/5/1/12</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Benzodiazepine-use_S2 (yes/no)</td>
<td>N</td>
<td>–</td>
<td>4*/15</td>
<td>3*/d/17</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

HC, healthy control; S-R, symptom-remitted MDD patients; S-S, symptomatic-symptomatic MDD patients; SAD, social anxiety disorder; PD, panic disorder; GAD, generalized anxiety disorder.

*HC differed from both patient groups, while the two patient groups did not differ.
*All groups differed from each other.
*Infrequent use.
*Two patients used benzodiazepine frequently.
*Significant at p < 0.05.
Task paradigm

All participants performed the event-related, subject-paced, emotional word encoding and recognition task during both fMRI scanning sessions (S1 and S2) (van Tol et al., 2012). During the encoding phase, 20 blocks containing 160 stimuli (positive/negative words and baseline trials; 40 each) were pseudorandomly presented. Participants were instructed to evaluate whether the word was positive, negative, or neutral in valence by pressing the right, left, and middle button, respectively. During baseline trials, participants were asked to press the corresponding button to indicate the direction of the arrow. After a retention interval of 10 min (during which the structural T1 scan was acquired), the retrieval phase started and consisted of 120 encoding target words, 120 distractor words, and 40 baseline words that were presented in 20 pseudo-randomized blocks. Participants were instructed to indicate whether they had seen, had not seen, or probably had seen the word. Emotional words in the valence categories were matched based on length, frequency in the Dutch language, and complexity. The same words list was used in both measurements, although the order was changed at the 2-year follow-up measurement. The emotional word encoding task was preceded by an executive planning task (van Tol et al., 2011) and followed by an emotional face viewing task (Demeneșcu et al., 2011; Opmeer et al., 2015) and a resting state acquisition (Veer et al., 2010). Based on the hypotheses formulated in our cross-sectional study (van Tol et al., 2012), we only investigated the encoding session.

fMRI data acquisition

Neuroimaging data were collected with 3T Philips MR-scanners located in Amsterdam, Leiden, and Groningen using standard EPI techniques, though with minor differences in acquisition parameters. A detailed description of acquisition specifications can be found in the online Supplementary material.

Data analysis

Independent variables

Firstly, to test for the correlation between symptom change and brain activation change over time, a relative symptom change score representing the difference in depression severity between S1 and S2 while taking into account baseline severity was calculated for each patient [i.e. (MADRS S2–MADRS S1)/MADRS S1]. Furthermore, to be able to compare changes over time in behavior and brain activation following symptomatic change with changes in HC, HC were also scanned twice, and to explore, e.g. whether change in the high improved patients represented normalization (i.e. approached activation of HC at S2) or whether change in low improved patients represented further deviations from normal, we divided the patients in two groups based on the median of relative symptom change scores (median = −0.46): a group of high improved (MDD-HI; n = 20, online Supplementary Fig. S1) and a group of low improved patients (MDD-LI; n = 19).

Secondly, to test for the correlation between brain activation change and percentage of time spent with depression (i.e. persistence), presence of depressive symptoms per month for the duration of the interval between S1 and S2 was assessed with the life chart interview (Lyketsos et al., 1994) at S2. Participants had to rate the severity of depressive symptoms per month and only symptoms with small to severe burden were taken as an indication of the presence of symptoms. Percentage of months experiencing depressive symptoms relative to the overall follow-up period was calculated per patient as the time spent with depression (Ai et al., 2015).

Clinical variables and behavioral data

Effects of symptom change and time spent with depressive symptoms on demographic, psychometric assessment, and memory performance were analyzed in IBM SPSS software (SPSS v.22.0, IBM). We employed analyses of covariance (ANCOVA), $\chi^2$ tests and t tests where appropriate for demographic and psychometric data with a significance level of $p < 0.05$, two-tailed.

For the behavioral data, performance difference scores (S2 − S1) for both reaction times (RT) and accuracy for successfully encoded words (Tulving, 1985) were calculated. We assessed the continuous association between relative symptom change scores and depressive duration, and RT and accuracy difference scores over time in patients. Age and years of education were included as covariates. A sensitivity analysis was performed within patients who showed symptomatic improvement (thus, patients who were equally or more depressed at S2 than at S1 were excluded; n = 6).

Additionally, to investigate whether patients (MDD-HI/LI) performed differently over time as compared to HC, we set up a group (3; HC, HI, LI) × valence (3; positive, negative, neutral) × time (2; S1, S2) repeated-measures ANCOVA, with age and years of education as covariates. Effects were considered significant at $p < 0.05$. Where appropriate, Bonferroni correction for multiple comparisons was applied.

Imaging data preprocessing

For the fMRI data, preprocessing and task modeling was performed with Statistical Parametric Mapping software (SPM8, Wellcome Trust Center for Neuroimaging, http://www.fil.ion.ucl.ac.uk/spm) implemented in Matlab 7.8 (The Math Works Inc., Natick, MA, USA). A detailed description of the preprocessing steps and first-level modeling can be found in the online Supplementary material.

Effects of change of depressive state

To test for the association between symptom change and change of brain activation during positive and negative encoding over the 2-year interval, scan moments, S2 − S1 contrast maps were entered as dependent variables in a full-factorial model, with valence (successfully encoded positive words>successfully encoded neutral words) as an interacting factor with valence. Contrast maps were built for the successful encoding of positive words (vs. successful encoding of neutral words) and negative words separately. To control for the possible confounding effects of variations within and between participants in scanning site (which coincided with minor variations in sequence and coil; see online Supplementary material), four dummy variables for site (i.e. both times scanned in AMC; changed from AMC to LUMC; changed from LUMC to AMC; both times scanned in UMCG; both times scanned in LUMC) were defined as covariates of no interest. In addition, age and years of education at S1 were added as covariates.

We repeated our analysis with the following possible confounding factors added separately to the model: percentage of time spent with depression, relative changes in anxiety severity assessed by Beck Anxiety Inventory [(BAI-scores S2 − S1)/BAI-scores S1] (Beck et al., 1988), SSRI-use, and participation in the life chart interview (Lyketsos et al., 1994) at S2. Participants had to rate the severity of depressive symptoms per month and only symptoms with small to severe burden were taken as an indication of the presence of symptoms. Percentage of months experiencing depressive symptoms relative to the overall follow-up period was calculated per patient as the time spent with depression (Ai et al., 2015).
in psychotherapy, SSRI-use at/between S1 and S2 was added to the model by means of three dummy variables (used at both S1 and S2, started after S1, stopped after S1, both not used). Psychotherapy-use between S1 and S2 was coded as a dummy variable and added as a covariate to test for the effect of psychotherapy. Use of SSRI and psychotherapy between S1 and S2 are summarized in online Supplementary Table S1.

A sensitivity analysis was planned to test whether associations would hold in the analysis including only patients with symptomatic improvement (n = 33).

**Effects of the persistence of depressive symptoms**

We built a full factorial model with valence as factor (2; successfully encoded positive words>successfully encoded neutral words and successfully encoded negative words>successfully encoded neutral words) and time spent with depressive symptoms as an interacting covariate with valence. Site (four dummy variables), age, and years of education were added as covariates. We tested for the effects of time spent with depressive symptoms during encoding of positive words and negative words separately. In a subsequent step, relative symptom change of depressive and anxiety symptom severity and treatment at S1 and S2 (medication- and psychotherapy use; yes/no) were added separately as covariates to statistically control for their possible confounding effects.

A sensitivity analysis was planned within patients with symptomatic improvement.

**Statistical thresholding**

Based on previous studies (see Introduction), we *a priori* defined the bilateral hippocampus and amygdala as our regions-of-interest (ROI) and built one composite mask encompassing these regions. The regions were defined according to the automated anatomical labels of the Wake Forest University (WFU, Winston Salem, North Carolina) Pick Atlas toolbox. Small volume correction for multiple comparisons was applied within the ROI. *F*-tests in the main and follow-up analyses were explored separately for positive and negative words at p < 0.001 uncorrected. *Post hoc* t-tests were regarded significant at a threshold of p < 0.05 family wise error (FWE) corrected at voxel-level (with an initial threshold of p < 0.001 uncorrected). We also examined the effects in other brain regions than ROIs, which had to meet p < 0.05, FWE whole-brain corrected to be considered significant.

**Results**

**Demographic characteristics**

Demographics and clinical characteristics of all patients and HCs are summarized in Table 1 and online Supplementary material. Clinical characteristics of high-improved and low-improved patient groups that were included in explorative *post hoc* analyses are listed in online Supplementary Table and results. Thirty-three patients showed symptomatic improvement (S2 < S1), two remained stable (S2 = S1), and four showed more severe symptoms at S2 (S2 > S1).

**Behavioral results**

No correlations were found between relative depressive symptom change and changes in performance on the memory of positive, neutral, or negative words over time (i.e. RTs and accuracy) (p > 0.05). Sensitivity analyses within symptomatically improved patients only (n = 33) did not change this result. Group × time repeated-measures analysis of variance indicated no changes in the performance and response times in HC nor a difference between HC and HI or LI (p > 0.05).

There was no association between time spent with depressive symptoms and changes in behavioral performance (p > 0.05).

**fMRI results**

**Correlations with change of depressive state**

Relative symptom change was negatively correlated with activation change in the bilateral hippocampal/amygdala during both positive and negative word encoding (Table 2; Fig. 1). However, only the effect in the left hippocampus survived multiple comparison correction and indicated that larger symptomatic improvement coincided with a larger increase in left anterior hippocampal activation during encoding of emotional information.

Adding time spent with depressive symptoms in the interval between S1 and S2 as covariate did not change the results [Z = 3.85, P_{FWE} = .019 for successfully encoded positive words>successfully encoded neutral words (pos); Z = 3.95, P_{FWE} = .014 for successfully encoded negative words>successfully encoded neutral words (neg)]. Also, results were not affected by including change in anxiety severity as a covariate to the model (pos: Z = 3.82, P_{FWE} = .021; neg: Z = 3.77, P_{FWE} = .025) or by adding SSRI-use at S1 and S2 as covariates (pos: Z = 3.68, P_{FWE} = 0.034; neg: Z = 3.49, P_{FWE} = 0.06). Results bordered statistical significance after adding psychotherapy as a covariate (pos: Z = 3.59, P_{FWE} = 0.05; neg: Z = 3.54, P_{FWE} = 0.05).

When repeating the analysis in the symptomatically improved patients only, the negative correlation between symptom change and brain activation change in the hippocampus was observed subthreshold [MNI coordinates (x = −18, y = −13, z = −11), Z = 3.51, P_{FWE} = .09] during positive encoding, and was not significant during negative encoding (P_{FWE} = .50).

Furthermore, *post hoc* group comparison (detailed in the online Supplementary methods and results) showed that activation estimates in our main cluster did not change in HC over time, and plots suggested a trend of normalization during positive but not negative word encoding in the high-improved group (online Supplementary Fig. 3A and 3B).

**Correlations with time spent with depressive symptoms and course**

No correlation between the percentage of time with depressive symptoms and changes in brain activation was observed across all MDD patients during successful encoding on positive and negative words. Adding change in depressive and anxiety symptoms or medication/therapy use to the model did not change this observation.

**Discussion**

In this longitudinal study, we examined changes in emotion-related brain activation over time associated with symptomatic improvement and time spent with depressive symptoms in depressed patients. Symptomatic improvement was associated with increased responses in the anterior hippocampus/amygdala during encoding of emotional stimuli over time. Follow-up explorations indicated that increased activation of the hippocampal/amygdala responsiveness occurred in the direction of normalization, especially for the encoding of positive words. The effect
was unrelated to changes in anxiety severity, and use of SSRIs, although it became smaller after adding use of psychotherapy as a covariate. No relation was observed between depression duration (i.e. time spent with depressive symptoms) in the 2-year follow-up nor were changes in hippocampal and amygdalar activation observed. These results suggest that hippocampal activation during emotional memory formation changes with symptomatic improvement, but is not subject to functional ‘scarring’ as a result of enduring symptom manifestation. Our results indicate that symptomatic improvement is at least partially associated with normalization of limbic responsiveness to positive material.

Based on previous reports on memory bias-related brain activation abnormalities in depression (Ramel et al., 2007; Hamilton and Gotlib, 2008; Van Wingen et al., 2010; Arnold et al., 2011; van Tol et al., 2012) and our previous cross-sectional observations (van Tol et al., 2012), we hypothesized state-dependency of activation of the amygdala and hippocampus specific for negative valence information, and thus changes of activation as a function of symptomatic recovery. In line with this hypothesis, hippocampal reactivity during negative encoding correlated with symptomatic change. Moreover, state-dependency was observed during positive encoding. Although similar linear relations with symptomatic improvement were observed for both positive and negative encoding, changes during positive word encoding showed to be a more specific indicator of symptomatic improvement. This was indicated by the stability of effects when excluding the patients that worsened in terms of symptom severity and by the fact that the post hoc plotting of effects indicated an increase of activation in the improved patients only. This increase followed a pattern of normalization (i.e. approaching activation in the HC). During negative encoding, associations were no longer significant when studied in the symptomatic improved patients only. This suggests that state-dependent changes during positive encoding may be a preferred marker of symptomatic improvement. Notwithstanding, although longitudinal studies did not study emotional encoding for both positive and negative information so far, our study supports findings of altered reactivity to positive information (Fu et al., 2007; Victor et al., 2010; Wise et al., 2014), and suggests normalized reactivity to positive-related effects.

The hippocampus has been proposed as a target for both antidepressant treatment and cognitive behavioral therapy (CBT) (Goldapple et al., 2004). Treatment studies have confirmed the importance of the hippocampus by consistently reporting normalization of hippocampal activation following pharmacological treatment (Fu et al., 2004; Anand et al., 2007; Arnone et al., 2012b) and CBT (Goldapple et al., 2004; Ritchey et al., 2011). In the current study, we studied the neural characteristics related to naturalistic changes in a depressive state, which was not attributable to treatment with antidepressant medication. However, most of our sample received at least one type of psychological care. Therefore, we cannot fully rule out the effect of psychotherapy and indeed our effects were slightly attenuated when treatment with psychotherapy was added to the model. Together, our observations suggest that increased hippocampal responsiveness to emotional material may not only reflect treatment effects of or symptomatic improvement following antidepressants or psychological treatment (Fu et al., 2007; Victor et al., 2010; Wise et al., 2014) but also naturalistic improvement.

No other regions were found to change as a function of symptomatic improvement. Although changes in regions such as the ventromedial prefrontal cortex (Ritchey et al., 2011), anterior cingulate cortex (Fu et al., 2008), frontal pole (Usami et al., 2014), and the extrastriate cortex (Fu et al., 2007) have been reported by previous longitudinal treatment studies. They have been reported in the context of emotional processing, but not in the context of memory formation or using verbal stimuli. Additionally, other studies have reported that prefrontal alterations might be a trait marker rather than a state marker of vulnerability to depression (Elliott et al., 2012; Tomioka et al., 2015), which was not the focus of our study.

The second aim of this study was to investigate whether time spent with depressive symptoms was associated with greater functional brain alterations during emotional memory encoding. We found that depression duration was not correlated with changes of activation in the hippocampus, which indicates that the neurotoxic or scarring hypothesis might not be relevant to functional changes over time. Previous cross-sectional and longitudinal studies suggested that hippocampal volume is negatively related to the duration of illness in MDD, represented by the history of psychiatric hospitalization (Zaremba et al., 2018), number of episodes.

<table>
<thead>
<tr>
<th>Regions</th>
<th>MN1 coordinate</th>
<th>k</th>
<th>k*</th>
<th>Side</th>
<th>BA</th>
<th>x</th>
<th>y</th>
<th>z</th>
<th>T</th>
<th>Z</th>
<th>p_FWE_SVC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Successfully encoded positive words&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Successfully encoded neutral words: negative correlation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hippocampus/amygdala</td>
<td>35</td>
<td>13</td>
<td>L</td>
<td>20</td>
<td>−27</td>
<td>−16</td>
<td>−11</td>
<td>3.83</td>
<td>3.63</td>
<td>0.040*</td>
<td></td>
</tr>
<tr>
<td>Hippocampus/amygdala</td>
<td>33</td>
<td>9</td>
<td>R</td>
<td>34</td>
<td>27</td>
<td>−4</td>
<td>−11</td>
<td>3.46</td>
<td>3.31</td>
<td>0.107</td>
<td></td>
</tr>
<tr>
<td>Successfully encoded negative words&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Successfully encoded neutral words: negative correlation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hippocampus/amygdala</td>
<td>50</td>
<td>22</td>
<td>L</td>
<td>-</td>
<td>-24</td>
<td>-13</td>
<td>-11</td>
<td>3.76</td>
<td>3.57</td>
<td>0.049*</td>
<td></td>
</tr>
<tr>
<td>Hippocampus/amygdala</td>
<td>59</td>
<td>20</td>
<td>R</td>
<td>-</td>
<td>15</td>
<td>-7</td>
<td>-17</td>
<td>3.40</td>
<td>3.26</td>
<td>0.122</td>
<td></td>
</tr>
</tbody>
</table>

*aCluster size in whole-brain analysis.
*bCluster size after small volume correction.
*Significant at p < 0.05 FWE corrected, voxel-level after small volume correction (SVC).
(MacQueen et al., 2003; Treadway et al., 2015), and duration of untreated illness (Sheline et al., 1999), though not consistently (Bremner et al., 2000; McKinnon et al., 2009). At the same time, volumetric changes in the hippocampus have been linked to symptomatic improvement following treatment (Arnone et al., 2012a), suggesting state-dependency of hippocampal volume. In the present study, though patients differed in course trajectory of depression, changes of brain activation were not related to the depressive course, indicating that functional longitudinal changes observed in the hippocampus are load-independent. However, the variety in selected clinical variables of current and previous studies might explain some heterogeneity in reported results. Together, our results indicate that functional responsiveness of limbic brain regions may be more related to a depressive state, without exacerbation of abnormalities as a function of unfavorable course of the depression.

Some limitations of our study should be noted. First, although clear strengths of our study are its longitudinal naturalistic design and that we could control for activation changes over the same interval in a healthy sample, the associations we found between changes of brain activation and symptom change over time are correlational in nature and do not imply causation of remission in depression. This effect was not found in a formal group × time × valence interaction. However, testing this was not the aim of our paper because we focused on changes over time within depressed patients. Second, we investigated symptom severity change of depression rather than symptom remission. Although most of our high-improved patients were recovered at the time of the follow-up measurement, our conclusions cannot be generalized to changes associated with stable remission. Third, although adding SSRI-use and psychotherapy use as covariates to the model did not change the observed relations, this does
not fully rule out specific medication/treatment effects. Fourth, caution should be taken in interpreting our result as a true memory effect (i.e. hits–misses), because the number of error trials was too low to investigate this. More sensitive measures on behavioral changes in primary emotional and memory processing are necessary in future studies. Fifth, although the site effect was controlled by adding it as a covariate, it might still have a confounding effect on our results. Quality assurance analysis and exploration by excluding patients that switched scanners between measurements (online Supplementary results) revealed similar results. These indicate that our observed effects, especially those observed during positive encoding, were not primarily driven by site-specific changes in signal over time. Next, the retrospective life chart method used to measure the persistence of depressive symptoms might have been subject to patients’ mood state, though the reliability and validity have been estimated to be relatively high (Warshaw, et al., 2001). Furthermore, although comorbidity of SAD and PD was similar in low- and high-improved MDD groups, GAD was more frequent in low-improved MDD patients, which may have affected our results. Finally, it is possible that the encoding processing was more explicit at S2 than at S1, because people at S2 could have remembered that a recognition phase followed the encoding phase. However, implicit and explicit memory processing have been suggested to be subject to the same encoding factors and rely on similar perceptual processes and representations (Turk-Browne et al., 2006), which is corroborated by the lack of differences over time in the HC group in our study.

Conclusion

By characterizing longitudinal changes of activation in the anterior hippocampus/amygdala during emotional memory encoding, our study showed that the neural correlates of emotional memory formation change with the improvement of the depressive state. Furthermore, our findings suggest a normalization of activation, especially for positive information. On the other hand, enduring depressive symptom manifestation was not related to longitudinal changes in hippocampal–amygdalar activity. Taken together, our results suggest that hippocampal activation is a state-dependent characteristic that is not related to the persistence of depression. This may indicate that functional activation patterns in depression are not subject to functional ‘scarring’, a hypothesis that deserves further investigation.

Supplementary material. The supplementary material for this article can be found at https://doi.org/10.1017/S0033291719001259.

Acknowledgments. This study is supported by the participating universities and mental health care organizations: VU University Medical Center Amsterdam, University Medical Center Groningen, Leiden University Medical Center, GGZ inGeest, Arkin, GGZ Rivierduinen, Lentinis, GGZ Friesland, GGZ Drenthe, Scientific Institute for Quality of Healthcare (IQ healthcare), The Netherlands Institute for Health Services Research (NIVEL), and The Netherlands Institute of Mental Health and Addiction (Trimbos Institute).

Financial support. Hui Ai is jointly supported by the National Natural Science Foundation of China (grant no. 31770959 and 31871137), Young Elite Scientists Sponsorship Program by CAST, YESS, Shenzhen Peacock Program (827-000235 and KQTD201503301604926) and Guangdong Pearl River Talents Plan for Postdoctoral researchers. Marie-José van Tol was supported by a VENI grant from the Netherlands Organization for Scientific Research (N.W.O.) (grant no. 016.156.077). Esther Opmeer is partly supported by a grant from N.W.O. ZonMw (grant no. 537001005). The infrastructure for the NESDA study (http://www.nesda.nl) is funded through the Geestkracht program of the Netherlands Organisation for Health Research and Development (ZonMw, grant no. 10-000-1002) and financial contributions by participating universities and mental health care organizations (VU University Medical Center, GGZ inGeest, Leiden University Medical Center, Leiden University, GGZ Rivierduinen, University Medical Center Groningen, University of Groningen, Lentinis, GGZ Friesland, GGZ Drenthe, Rob Giel Onderzoekcentrum).

Conflict of interest. Hui Ai, Jan-Bernard C. Marsman, Dick J, Veltman, and Esther M. Opmeer declare no conflict of interest. Nic van der Wee received speaking fees from Eli Lilly and Wyeth; and served on advisory panels of Eli Lilly, Pfizer, Wyeth, and Servier. Marie-José van Tol received speaker fees from Lundbeck n.v. André Alemann received an investigator-initiated unrestricted research grant from Bristol-Myers Squibb and speakers bureau honoraria from Lundbeck n.v. All of these activities are not directly related to the present study and, therefore, do not form a conflict of interest.

Ethical standard. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.

References


neuroimaging findings. The Australian and New Zealand Journal of Psychiatry 51, 441–454.


